WEC
RGNX icon

Winslow Evans & Crocker’s Regenxbio RGNX Stock Holding History

Winslow Evans & Crocker’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-142
Closed -$5K – 1142
2020
Q2 		$5K Hold
142
– – ﹤0.01% 894
2020
Q1 		$6K Hold
142
– – ﹤0.01% 834
2019
Q4 		$6K Hold
142
– – ﹤0.01% 951
2019
Q3 		$6K Buy
+142
New +$5.75K ﹤0.01% 935

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Winslow Evans & Crocker's RGNX Position: Q3 2020 in Review

Winslow Evans & Crocker sold out of Regenxbio (RGNX) in Q3 2020, closing a stake of 142 shares — an estimated $5K sold.

Winslow Evans & Crocker first reported a position in RGNX in Q3 2019 and held it in 4 quarters. The position peaked at $6K in Q1 2020. 166 funds tracked by Wall St. Rank hold RGNX as of Q3 2020.

  • Winslow Evans & Crocker reported no remaining Regenxbio position as of Q3 2020 after selling out during the quarter.
  • Winslow Evans & Crocker sold 142 Regenxbio shares in Q3 2020, an estimated $5K.
  • Winslow Evans & Crocker first reported a position in Regenxbio in Q3 2019 and held it in 4 quarters.
  • Winslow Evans & Crocker's Regenxbio position peaked at $6K in Q1 2020.
  • 166 funds tracked by Wall St. Rank held Regenxbio as of Q3 2020.

Based on Winslow Evans & Crocker's 13F filing for Q3 2020, filed 21 Oct 2020.